A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONCUR
  • Sponsors Bayer
  • Most Recent Events

    • 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2016 Results of plasma protein biomarker analysis will be presented at the 2016 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, according to a Bayer media release.
    • 14 Sep 2015 Results of biomarker analysis will be presented at the 2015 European Cancer Congress, according to a Bayer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top